Market revenue in 2023 | USD 337.6 million |
Market revenue in 2030 | USD 500.7 million |
Growth rate | 5.8% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 65.73% in 2023. Horizon Databook has segmented the Italy blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Furthermore, the increasing focus on precision medicine and personalized treatment approaches has driven the demand for advanced diagnostic technologies, such as metabolomics, to better understand the metabolic rewiring associated with cancer and develop more effective therapeutic strategies.
In March 2020, Japan's AGC (formerly Asahi Glass Chemical) launched a voluntary tender offer to acquire the Italian clinical-stage biotech company Molecular Medicine (Molmed). Molmed is focused on research, development, manufacturing, and clinical validation of gene & cell therapies, and it offers GMP services for third parties, including leading European and U.S. companies.
Molmed's most advanced product is a Chimeric Antigen Receptor-T (CAR-T) cell therapy for acute myeloid leukemia and multiple myeloma. In addition, it is developing a pipeline based on natural killer cells. Such advances are driving market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Italy blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account